So far, even angiogenesis receptor inhibitors are inefficient against many tumor types, either because tumor growth factor receptors differ, or because angiogenesis is dependent on non-VEGF pathways, as in lung cancer. This evidence concerns the gene VEGFA and lung carcinoma.